Advertisement

Therapeutic Efficacy of Oxazaphosphorines by Immunomodulation

  • R. Voegeli
  • J. Pohl
  • T. Reissmann
  • J. Stekar
  • P. Hilgard
Part of the NATO ASI Series book series (NSSA, volume 120)

Abstract

Cyclophosphamide and a few related compounds of the class of oxazaphosphorines are widely used in the chemotherapy of malignant diseases. Their antitumour efficacy is based on their cytotoxic activity against quickly proliferating cells. Beside this, these agents are strong immunosuppressants and a particularly high sensitivity of antibody-producing, proliferating B cells was postulated (1). In contrast, it could be shown that cyclophosphamide in non-toxic doses enhanced delayed-type hypersensitivity reactions, which indicated a selective effect of cyclophosphamide on T cells (2,3).

Keywords

Antitumour Efficacy Modify Cell Surface Human Peripheral Mononuclear Cell Adjuvant Combination Chemotherapy Host Antitumor Immunity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    I. McConnell, A. Munro, and H. Waldman, “The Immune System: A Course on the Molecular and Cellular Basis of Immunity”, The Alden Press, Oxford (1981).Google Scholar
  2. 2.
    P. W. Askenase, B. J. Hayden, and R. K. Gershon, Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody response, J. Exp. Med., 141: 697–702 (1975).PubMedCrossRefGoogle Scholar
  3. 3.
    A. Mitsuoka, M. Baba, and S. Morikawa, Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice, Nature, 262: 77–78 (1976).PubMedCrossRefGoogle Scholar
  4. 4.
    D. Bernd, M. J. Mastrangelo, P. F. Engstrom, A. Paul, and H. Maguire, Augmentation of the human immune response by cyclophosphamide, Cancer Res., 42: 4862–4866 (1982).Google Scholar
  5. 5.
    D. Bernd, H. C. Maguire, Jr., and M. J. Mastrangelo, Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer, Cancer Res., 44: 1275–1280 (1984).Google Scholar
  6. 6.
    R. C. Bast, Jr., E. L. Reinherz, C. Mayer, P. Lavin, and S. F. Schlossman, Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes, Clin. Immunol. Immunopathol., 28: 101–114 (1983).Google Scholar
  7. 7.
    J. L’Age-Stehr and T. Diamantstein, Induction of autoreactive T lymphocytes and their suppressor cells by cyclophosphamide, Nature, 271: 663–665 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    H. Grunicke, H. Putzer, F. Scheidl, and E. Wolff-Schreiner, The cell surface as a target for alkylating agents, in: “The control of tumour growth and its biological bases”, W. Davis, C. Maltoni, and S. Tanneberger, eds., Akademie-Verlag, Berlin (1983).Google Scholar
  9. 9.
    J. C. D. Hengst, M. B. Mokyr, and S. Dray, Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice, Cancer Res., 40: 2135–2141 (1980).PubMedGoogle Scholar
  10. 10.
    J. C. D. Hengst, M. B. Mokyr, and S. Dray, Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors, Cancer Res., 41: 2163–2166 (1981).PubMedGoogle Scholar
  11. 11.
    M. B. Mokyr, J. C. D. Hengst, and S. Dray, Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors, Cancer Res., 42: 974–979 (1982).PubMedGoogle Scholar
  12. 12.
    Proc. Satellite Meeting 10th Int. Symposium on the Biological Characterization of Human Tumors, Brighton, Invest. New Drugs, 2: 129–259 (1984).Google Scholar
  13. 13.
    J. Pohl, P. Hilgard, W. Jahn, and H. J. Zechel, Experimental toxicology of ASTA Z 7557 (INN mafosfamide), Invest. New Drugs, 2: 201–206 (1984).PubMedCrossRefGoogle Scholar
  14. 14.
    Internal Report, Asta-Werke AGGoogle Scholar
  15. 15.
    K. Powell, A. Buzdar, T. Smith, and G. Blumenschein, Subsequent malignant neoplasma in stage II, III breast cancer patients treated with and without adjuvant combination chemotherapy, Proc. ASCO, 1:C-301 (1982).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • R. Voegeli
    • 1
  • J. Pohl
    • 1
  • T. Reissmann
    • 1
  • J. Stekar
    • 1
  • P. Hilgard
    • 1
  1. 1.Department of Experimental Cancer ResearchAsta-Werke AG Degussa Pharma GruppeBielefeld 14Germany

Personalised recommendations